Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients

Inclusion Criteria: * Patients who were diagnosed by the histologic, cytologic diagnosis of IIIB (malignant hydrothorax or hydropericardium) or IV non-small cell lung cancer * ≥ 18 years old * patients who have received more than one regimen of platinum-based chemotherapy; patients who have received EGFR monoclonal treatment could also be enrolled * At least one target lesion diameter spiral CT ≥ 1 cm, or the common CT ≥ 2 cm, and can be measured by imaging tools * have an interval of more than 4 weeks from the last chemo- or radio-therapy; 2 weeks from the last targeted therapy * ECOG 0-2 * Expected life time longer than 3 months * Normal laboratory values: * leucocyte≥ 4×109/L * neutrophil≥ 1.5×109/L * platelet≥90×109/L * Hemoglobin≥ 9g/L * ALT and AST ≤3×ULN (≤5×ULN if liver metastasis) * serum creatinine\<1.5 mg/dl * bilirubin \<1.5×ULN * No allergy to biological drug * Sign the consent forms Exclusion Criteria: * Patients who have previously received Docetaxel or anti-VEGF inhibitors * Severe symptomatic heart disease * Female patients during their pregnant and lactation period, or patients without contraception * Severe uncontrolled infection * Uncontrolled neurologic or psychiatric disease; Uncontrolled primary or metastatic brain tumor * Patients with other malignant tumor,except for basal cell carcinoma,squamous cell carcinoma and carcinoma in situ * Patients have accepted other clinical trials